Twist Bioscience is surging as investors react to a series of high-profile data and services agreements, most notably a deal to power Eli Lilly’s AI/ML TuneLab antibody discovery platform. This momentum is further supported by broader optimism surrounding the company's synthetic DNA technology and its role in the rapidly expanding oligonucleotide synthesis reagents market, which is projected to reach 1.75 billion dollars by 2033. While the stock has seen varying degrees of upward movement in recent sessions following these strategic announcements, the current rally reflects sustained confidence in the company's growth trajectory within the biotechnology sector.